A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy

Condition:   Breast Cancer, Early Breast Cancer Interventions:   Drug: Camizestrant;   Drug: Tamoxifen;   Drug: Anastrozole;   Drug: Letrozole;   Drug: Exemestane Sponsor:   AstraZeneca Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials